Company Summary - GlaxoSmithKline PLC (LSE:GSK)
1,253.50p
13.00p
(1.04%)
FTSE 100 Pharmaceuticals & BiotechnologyMarket cap: £65,045.185m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
The group is a healthcare group engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Pharmaceutical products include medicines in the following therapeutics areas: respiratory, central nervous systems, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, anti-bacterial, oncology and emesis
| Financials - 3rd Quarter (28/10/2009) | ||
|---|---|---|
| Turnover | £m | 20,274 |
| Pre-tax Profit | £m | 5,641 |
| EPS | p | 82.92 |
| DPS | p | 45.00 |
| Director | Board Role |
|---|---|
| Sir Christopher Gent | Chairman |
| Andrew Witty | Chief Executive |
| Julian Heslop | Finance Director |
Products Brands & Subsidiaries
Products & Brands
Agenerase; Amoxil; Augmentin; Avandia; Beconase; Becotide/Beclovent; Combivir/Biovir; Coreg; Engerix-B; Epivir/3TC...
Subsidiaries
Glaxo Operations UK Ltd; Wellcome Ltd; The Wellcome Foundation Ltd; Glaxo Group Ltd; SmithKline Beecham (Cork) Ltd...
Broker Sentiment (11 brokers)
| Heading | Date |
|---|---|
| Net Asset Value(s) | 20/11/2009 |
| Net Asset Value(s) | 19/11/2009 |
| Blocklisting Interim Review | 18/11/2009 |
For more information
and investor relations, visit the
GlaxoSmithKline PLC company website: